MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells

Oncotarget

Volumn 5, Issue 19, 2014, Pages 8893-8905

  Kharbanda, Akriti ^a   Rajabi, Hasan ^a   Jin, Caining ^a   Alam, Maroof ^a   Wong, Kwok Kin ^a   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AKT; EMT; KRAS; MUC1 C; NSCLC; Self renewal; ZEB1

Indexed keywords

ANTINEOPLASTIC AGENT; GO 203; MICRORNA 200C; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; MUCIN 1 C; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; (ARGININE)9-CYSTEINYL-GLUTAMINYL-CYSTEINYL-ARGINYL-ARGINYL-LYSYL-ASPARAGINE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; HOMEODOMAIN PROTEIN; KRAS PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MUC1 PROTEIN, HUMAN; ONCOPROTEIN; OXADIAZOLE DERIVATIVE; PEPTIDE; PROTEIN KINASE B; RAS PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; LUNG CARCINOGENESIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; RNA INTERFERENCE; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE 1; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MUCIN-1; NEOPLASM TRANSPLANTATION; OXADIAZOLES; PEPTIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84910072604     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2360     Document Type: Article

References (43)

1. Pylayeva-Gupta Y, Grabocka E and Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11:761-774.
2. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A and et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14:1351-1356.
3. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S, Chan EM, Sos ML and et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009; 462:108-112.
4. Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, EastP, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, Stamp G, Behrens A and Downward J. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 2012; 149:642-855.
5. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, KhanG, Guerra C, Santamaria D and Barbacid M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010; 18:63-73.
6. Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS and Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 2013; 3:548-563.
7. Singh A, Greninger P, Rhodes D, Koopman L, VioletteS, Bardeesy N and Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009; 15:489-500.
8. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005; 65:9455-9462.
9. Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H and Rong T. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 2010; 28:596-604.
10. Jarrard J, Linnoila R, Lee H, Steinberg S, Witschi H and Szabo E. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res. 1998; 58:5582-5588.
11. Awaya H, Takeshima Y, Yamasaki M and Inai K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol. 2004; 121:644-653.
12. Khodarev N, Pitroda S, Beckett M, MacDermed D, HuangL, Kufe D and Weichselbaum R. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009; 69:2833-2837.
13. MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L, Kufe DW and Weichselbaum R. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Medical Genomics. 2010; 3:16.
14. Kufe D. Mucins in cancer: function, prognosis and therapy. Nature Reviews Cancer. 2009; 9:874-885.
15. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, KharbandaS and Kufe D. MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signaling. Nat Cell Biol. 2007; 9:1419-1427.
16. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S and Kufe D. MUC1-C oncoprotein functions as a direct activator of the NF-?B p65 transcription factor. Cancer Res. 2009; 69:7013-7021.
17. Rajabi H, Alam M, Takahashi H, Kharbanda A, GuhaM, Ahmad R and D. K. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene. 2013; 33:1680-1689.
18. Alam M, Rajabi H, Ahmad R, Jin C and Kufe D. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget. 2014; 5:2622-2634.
19. Cheever MA, Allison JP, Ferris AS, Finn OJ, HastingsBM, Hecht TT, Mellman I, Prindiville SA, Viner JL, WeinerLM and Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15:5323-5337.
20. Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M and Kufe D. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 2007; 282:19321-19330.
21. Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S and Kufe D. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol. 2012; 40:1643-1649.
22. Kufe D. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther. 2009; 8:1201-1207.
23. Raina D, Ahmad R, Joshi M, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S and Kufe D. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009; 69:5133-5141.
24. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, RajabiH, Alam M, Shimamura T, Shapiro G, Supko J, Kharbanda S and Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Therapeutics. 2011; 10:806-816.
25. Mahoney CL, Choudhury B, Davies H, Edkins S, Greenman C, Haaften G, Mironenko T, Santarius T, Stevens C, Stratton MR and Futreal PA. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer. 2009; 100:370-375.
26. Brabletz S and Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep. 2010; 11:670-677.
27. Wu K, Fan J, Zhang L, Ning Z, Zeng J, Zhou J, Li L, Chen Y, Zhang T, Wang X, Hsieh JT and He D. PI3K/Akt to GSK3beta/beta-catenin signaling cascade coordinates cell colonization for bladder cancer bone metastasis through regulating ZEB1 transcription. Cell Signal. 2012; 24:2273-2282.
28. Chen W, Wu S, Zhang G, Wang W and Shi Y. Effect of AKT inhibition on epithelial-mesenchymal transition and ZEB1-potentiated radiotherapy in nasopharyngeal carcinoma. Oncol Lett. 2013; 6:1234-1240.
29. Dontu G, Abdallah WM, Foley JM, Jackson KW, ClarkeMF, Kawamura MJ and Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17:1253-1270.
30. Liao MJ, Zhang CC, Zhou B, Zimonjic DB, Mani SA, KabaM, Gifford A, Reinhardt F, Popescu NC, Guo W, Eaton EN, Lodish HF and Weinberg RA. Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res. 2007; 67:8131-8138.
31. Raina D, Kharbanda S and Kufe D. The MUC1 oncoprotein activates the anti-apoptotic PI3K/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem. 2004; 279:20607-20612.
32. Kufe D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013; 32:1073-1081.
33. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, MajumderPK, Baselga J and Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011; 19:58-71.
34. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K and Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000; 14:2501-2514.
35. Wang C, Lisanti MP and Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle. 2011; 10:57-67.
36. Sunaga N, Shames D, Girard L, Peyton M, Larsen J, ImaiH, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar A, Mori M and et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther. 2011; 10:336-346.
37. Mani SA, Guo W, Liao MJ, Eaton EN, AyyananA, ZhouAY, Brooks M, Reinhard F, Zhang CC, ShipitsinM, Campbell LL, Polyak K, Brisken C and et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
38. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, KulpAN, Qian D, Lam JS, Ailles LE, Wong M, JoshuaB, Kaplan MJ, Wapnir I and et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; 458:780-783.
39. Cui X. Reactive oxygen species: the achilles' heel of cancer cells? Antioxid Redox Signal. 2012; 16:1212-1214.
40. Kobayashi CI and Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J Cell Physiol. 2012; 227:421-430.
41. Gorrini C, Harris IS and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12:931-947.
42. Panchamoorthy G, Rehan H, Kharbanda A, Ahmad R and Kufe D. A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain. Hybridoma. 2011; 30:531-535.
43. Wei X, Xu H and Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor a. Mol Cell. 2006; 21:295-305.